Harvard Bioscience (HBIO) Profit After Tax (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Profit After Tax data on file, last reported at -$3.4 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 93.2% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was -$9.8 million, a 83.15% increase from a year earlier, with the FY2025 full-year figure at -$56.7 million, down 357.07% from the prior year.
• Profit After Tax for Q1 2026 stood at -$3.4 million, down from -$2.8 million in the prior quarter.
• Over the last five years, Profit After Tax for HBIO reached as high as $2.4 million in Q2 2022 and fell as low as -$50.3 million in Q1 2025.
• Historically, Profit After Tax has averaged -$5.0 million across 5 years, with a median of -$2.3 million in 2025.
• Across the five-year window, Profit After Tax soared 693.9% in 2022 and plunged 15916.67% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$1.7 million in 2022, then declined by 9.12% to -$1.8 million in 2023, then soared by 100.99% to $18000.0 in 2024, then plunged by 15916.67% to -$2.8 million in 2025, then decreased by 20.27% to -$3.4 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$3.4 million in Q1 2026, -$2.8 million in Q4 2025, and -$1.2 million in Q3 2025.